Diagnosis and Treatment of Pulmonary Hypertension From Bench to Beds
This book focuses on pulmonary arterial hypertension (PAH, Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, Group 4) among the various groups of pulmonary hypertension (PH) whose classification was updated into five major categories at t
- PDF / 10,054,249 Bytes
- 231 Pages / 439.42 x 683.15 pts Page_size
- 37 Downloads / 215 Views
From Bench to Bedside Yoshihiro Fukumoto Editor
123
Diagnosis and Treatment of Pulmonary Hypertension
Yoshihiro Fukumoto Editor
Diagnosis and Treatment of Pulmonary Hypertension From Bench to Bedside
Editor Yoshihiro Fukumoto Department of Internal Medicine Kurume University School of Medicine Kurume, Japan
ISBN 978-981-287-839-7 ISBN 978-981-287-840-3 (eBook) DOI 10.1007/978-981-287-840-3 Library of Congress Control Number: 2016961246 © Springer Science+Business Media Singapore 2017 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer Nature Singapore Pte Ltd. The registered company address is: 152 Beach Road, #22-06/08 Gateway East, Singapore 189721, Singapore
Preface
Scientific and clinical advances continue progressively in the field of pulmonary hypertension (PH). As the accumulated evidence expands, it is important to adapt our systems to keep up with the progress. In maintaining established diagnostics and therapeutics, we have to go forward with the new advances and their potentials. PH, defined as a mean pulmonary arterial pressure (PAP) ≥ 25 mmHg at rest as assessed by right heart catheterization, is characterized by elevated pulmonary arterial pressure and increased pulmonary vascular resistance. The classification of PH has been updated, in which five major categories of the disorder are classified, including (Group 1) pulmonary arterial hypertension (PAH), (Group 2) PH due to left heart disease, (Group 3) PH due to lung diseases and/or hypoxia, (Group 4) chronic thromboembolic PH, and (Group 5) others. Especially Group 1, PAH, is caused by small pulmonary artery obstruction due to vascular proliferation and remodeling, defined as mean PAP ≥ 25 mmHg and pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg, which is characterized by the presence of pre-capillary PH in the absence of other causes of pre-capillary PH, such as PH due to lung
Data Loading...
